Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer: A randomized controlled clinical study

To investigate the anti-tumor activity and tolerability of celecoxib as an adjuvant therapy for patients with metastatic colorectal cancer (CRC). In this randomized controlled study, 54 patients with metastatic CRC were randomized into 2 groups; the control group (n=28) which received 6 cycles of fo...

Full description

Saved in:
Bibliographic Details
Published in:Saudi medical journal 2022-01, Vol.43 (1), p.37-44
Main Authors: Mostafa, Tarek M, Alm El-Din, Mohamed A, Rashdan, Amira R
Format: Article
Language:English
Subjects:
Adjuvant treatment
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Camptothecin - therapeutic use
Cancer
Celecoxib
Celecoxib - therapeutic use
Colorectal cancer
Colorectal Neoplasms - drug therapy
Drug therapy
Fluorouracil
Humans
Leucovorin
Metastasis
Original
Testing
Vascular Endothelial Growth Factor A
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the anti-tumor activity and tolerability of celecoxib as an adjuvant therapy for patients with metastatic colorectal cancer (CRC). In this randomized controlled study, 54 patients with metastatic CRC were randomized into 2 groups; the control group (n=28) which received 6 cycles of folinic acid, fluorouracil and irinotecan (FOLFIRI) regimen (5-flourouracil, leucovorin, irinotecan), and the celecoxib group (n=26) which received 6 cycles of FOLFIRI regimen plus celecoxib 200 mg twice daily. The study duration was 3 months. Patients were assessed at baseline and at the end of intervention through the Response Evaluation Criteria in Solid Tumors objective response rate (ORR) and through evaluating the serum concentrations of vascular endothelial growth factor (VEGF), soluble factor-related apoptosis (sFAS), sFAS ligand (sFASL), and epithelial neutrophil-activating peptide -78 (ENA-78/CXCL5). Common Terminology Criteria for Adverse Events version 6.0 was used for evaluating drug-related toxicity. After intervention, celecoxib/FOLFIRI arm showed significant elevation in ORR as compared to FOLFIRI arm ( =0.001). As compared to FOLFIRI arm, celecoxib/FOLFIRI arm showed significantly lower VEGF (
ISSN:0379-5284
1658-3175
DOI:10.15537/smj.2022.43.1.20210574